International Liability for Damages Arising from the Risks of Scientific Development (COVID-19 Vaccines as an Example)
Abstract
The COVID-19 pandemic has prompted pharmaceutical companies to rapidly develop and produce vaccines and treatments to limit or prevent the virus's spread. This unprecedented scientific race has brought about numerous legal issues, particularly concerning the regulatory processes for approving these products by health authorities and specialized agencies. Some entities issued emergency use authorizations without completing the full duration of clinical trials, raising questions about the legality of these approvals and their implications for legal liability in the event of subsequent harm.
This situation introduces a crucial question regarding international liability for damages resulting from the risks associated with these scientific developments, especially concerning COVID-19 vaccines. The significance of this issue is underscored by the potential for long-term negative health effects that were not known or apparent at the time of approval. This raises legal inquiries about the nature of these risks and whether they justify an exemption from international liability, particularly if it is determined that the producing entities or authorizing countries complied with the scientific standards that were available at that time.
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.